The effects of intracarotidly injected endothe lin (ET)-1 (0.01-3 nmol) on the local cerebral blood vol ume (CBV) in the parietotemporal cortex were examined by the photoelectric method in 17 anesthetized cats. CBV reflects the cumulative dimensions of the cerebral mi crovessels. Low doses of ET -1 (0.01 and 0.1 nmol) elic ited mild but significant reductions in CBV without changes in the systemic arterial blood pressure (SABP). High doses of ET -1 (3 nmol) initially induced marked de clines of CBV, which were attributable to the significant falls in SABP. CBV subsequently exhibited significant increases. The CBV increases were not secondary to the accompanying elevations of SABP, since they were un-Endothelin (ET) is a 21-amino acid peptide, orig inally isolated by Yanagisawa et a1. (1988) from cul tured endothelial cells of the porcine aorta. Subse quently, three distinct isoforms of ET, designated as ET-1, ET-2, and ET-3 , were identified (Inoue et aI., 1989). Among these, only ET-1 is known to ex ist in vascular endothelial cells (Bloch et aI., 1989). ET-1, ET-2, and ET-3 are demonstrated in various nonvascular tissues including those of the brain (Sakurai et aI., 1992). Recently, two different sub types of human ET receptors, ETA and ETB, have been isolated (Sakurai et aI., 1992). The ETA recep tors exhibit a higher affinity to ET-1 than to ET-3 , while the ET B receptors show an equipotent affinity to all three ETs. In acute cerebrovascular disorders
affected by inhibition of the SABP changes after prein jection of BQ-123 (1 mg/kg), an ET antagonist specific to the ET A receptors. The CBV increases, however, were prevented by continuous administration of �-mono methyl-L-arginine (0.35 mg/kg/min), an inhibitor of nitric oxide synthesis, plus BQ-123. We conclude that while low doses of intravascular ET -1 constrict the cerebral microvessels, high doses of ET-l dilate the cerebral mi crovessels through the induction of nitric oxide probably in the cerebrovascular endothelium. Key Words: Cerebral blood volume-Cerebral microvessel-Endothelin Endothelium-derived relaxing factor-Nitric oxide Photoelectric method.
including subarachnoid hemorrhage and ischemic stroke, the plasma level of ET-1 has been reported to be elevated (Masaoka et aI., 1989; Ziv et aI., 1992) . It seems likely, therefore, that the cerebro vascular actions of ET circulating in the blood may play a significant role, whether it be primary or not, in the evolution of such pathologic processes (Ziv et aI., 1992) .
Although ET -1 consistently exerts potent vaso constrictive effects on removed segments of cere bral vessels in vitro (Jansen et aI., 1989; Saito et aI., 1989) , the actions of ET-1 on the cerebral vessels in vivo are not uniform. When applied from the ablu minal side, ET-l strongly constricts the pial and basilar arteries of various species (Mirna et aI., 1989; Robinson and McCulloch, 1990; Gotoh et aI., 1991) . Low doses of ET-1, however, may occasion ally dilate the pial arteries (Armstead et aI., 1989; Faraci, 1989) , probably through the induction of prostanoids and endothelium-derived relaxing fac tors (EDRFs) (Armstead et al., 1989; Faraci, 1989) .
The reported effects of intravascularly adminis tered ET -1 on the cerebral vessels are diverse. Mirna et a1. (1989) were unable to detect appreciable changes in the angiographically determined caliber of the canine basilar artery and attributed this to the presence of the blood-brain barrier (BBB). Gotoh and colleagues (1991) did not find any significant changes in the feline pial artery diameters following intracarotid injection of ET -1, even after opening of the BBB with a hyperosmolar agent. On the other hand, Garcia et al. (1991) , by employing an electro magnetic flowmeter, found that ET -1 in the range of 0.01-0.3 nmol consistently reduced the cerebral cir culation in goats. Using a laser-Doppler flowmeter, Willette et al. (1990) reported that while low doses of intracarotidly injected ET -1 increased the cere bral perfusion, high doses of ET -1 reduced the ce rebral perfusion in rats.
Due to these inconsistencies in the reported ac tions of intravascular ET -I on the cerebral vessels and perfusion and of the importance of the circulat ing ET-l under pathologic conditions, we reevalu ated the effects of intracarotidly administered ET-l on the cerebral microvasculature employing a new method in cats. Our photoelectric method (Tomita et aI., 1978 (Tomita et aI., , 1982 (Tomita et aI., , 1983 permits continuous, quan titative, and on-line measurement of the local cere bral blood volume (CBV), which parallels the cu mulative dimensions of the cortical microvessels.
METHODS
Seventeen cats of either sex weighing 2.2-3.7 kg were used. The animals were anesthetized by intraperitoneal injection of a-chloralose (50 mg/kg) and urethane (500 mg/kg). After endotracheal intubation, respiration was controlled with a respirator (Harvard model 662). A thin catheter was inserted into the left lingual artery and used for injecting drugs into the carotid artery. Another cath eter was inserted into the left femoral artery and used for monitoring the systemic arterial blood pressure (SABP). The MABP was calculated from the SABP. The temper ature of the animals was maintained at 37-37.soC employ ing a heating blanket.
The head of each animal was fixed in a stereotaxic headholder. The local CBV was measured continuously with a photoelectric apparatus consisting of a small lamp of 1.0 mm in outer diameter (Hamai Electric) and a silicon photodiode (Sharp Electric) covered with a band pass filter (Tomita et al., 1978 (Tomita et al., , 1982 (Tomita et al., , 1983 . Through a small cranial hole made in the left parietotemporal region, the small lamp was inserted obliquely into the brain tissue to -5 mm below the surface. The photodiode was attached to the skull just above the inserted lamp. The photodiode detected the intensity of transmitted light passing through a thin layer of cortex, which was then calibrated to the amount of CBV.
In six animals, 0.01, 0.1, 1, or 3 nmol of ET-l (Peptide Institute, Osaka, Japan) was injected into the carotid ar tery via the lingual artery within -10 s. The changes in SABP and CBV were recorded continuously for 15 min. In the initial part of the study, we found that 3 nmol of ET -1 elicited significant increases in CBV, which were accompanied by increases in SABP. To examine whether or not the CBV increases were secondary to the elevation in SABP, the SABP changes were inhibited by the pread ministration of BQ-123 (Banyu Pharmaceutical Co., To kyo, Japan), a new ET receptor antagonist (Ihara et aI., 1992) . In six cats, the SABP and CBV changes elicited by the intracarotid administration of ET -1 (3 nmol) at 3 min after intracarotid bolus injection of BQ-123 (1 mg/kg) were recorded.
Further, in five animals, we also examined the role of nitric oxide, a presumed EDRF, in the CBV increases occurring after high doses of ET-l. AP-Monomethyl-L arginine (L-NMMA; Calbiochem, La Jolla, CA, U.S.A.), a competitive inhibitor of nitric oxide synthesis (Palmer et aI., 1988) , was injected continuously into the carotid ar tery at a rate of 0.35 mg/kg/min. At 10 min after the ini tiation of L-NMMA, BQ-123 (1 mg/kg) was injected as a bolus into the carotid artery. The SABP and CBV changes induced by the intracarotid injection of ET-l (3 nmol) at 3 min after the administration of BQ-123 were recorded.
The data are presented as means ± SD. Statistical anal ysis was performed by Student's t test and Wilcoxon's signed rank test. Figure 1 shows an example of CBV and SABP recordings before and after intracarotid injection of either 0.01 or 3 nmol of ET-l . Immediately after the injection of 0.01 nmol of ET-l , CBV exhibited a mild but gradual decrease without noticeable changes in SABP. Following the injection of 3 nmol of ET-l , SABP showed a marked reduction, but subsequently recovered to the initial level. CBV also exhibited a rapid reduction, but then under went a marked increase exceeding the initial level. Figure 2 summarizes the time course of MABP following intracarotid injection of either 0.01, 0.1, 1, or 3 nmol of ET -1. There were no significant changes in MABP following the O.OI-nmol adminis tration. A minimal MABP reduction of -4.3 ± 2.1 mm Hg (p < 0.05) was observed at 1 min after the injection of 0.1 nmol. There were marked declines in MABP immediately after the intracarotid injec tion of either 1 nmol ( -36.0 ± 14.4 mm Hg; p < 0.01) or 3 nmol ( -35.8 ± 11.9 mm Hg; p < 0.01) of ET -1. MABP returned to and remained at the initial level in the I-nmol group, but revealed a significant increase of + 29.0 ± 15.9 mm Hg (p < 0.01) at 15 min in the 3-nmol group.
RESULTS
The time course of CBV following intracarotid injection of either 0.Q1, 0.1, 1, or 3 nmol of ET':1 is shown in Fig. 3 . Following the injection of either 0.01 or 0.1 nmol, CBV underwent mild but signifi cant decreases (from -6 to -13 %; p < 0.05) for > 15 min. Following the injection of 1 nmol, CBV was initially decreased (-0.71 ± 0.83 vol%), but remained at the control level thereafter. Following the 3-nmol administration of ET-l , CBV initially
• exhibited a -24% reduction ( -1.49 ± 1.00 vol%; p < 0.05), but gradually exceeded the control level and exhibited an increase of + 36% ( + 2.29 ± 1.93 vol%; p < 0.05) at 15 min. Figure 4 shows the effects of intracarotid injec tion of ET -1 (3 nmol) on MABP, when compared between the groups without any pretreatment, with preadministration of BQ-123 (1 mg/kg), and with continuous injection of L-NMMA (0.3 5 mg/kg/min) plus preinjection of BQ-123 (1 mg/kg). The pressor effect of ET-1 ( + 23 .0 ± 15.6 mm Hg at 10 min) was of CBV and SABP following in tracarotid injection of 0.01 or 3 nmol of ET-1. After the 0.01nmol injection, CBV exhibited a mild and gradual reduction without changes in SABP. Im mediately after the 3-nmol injec tion, CBV and SABP were mark edly decreased. Subsequently, CBV underwent an increase to above the control level, while SABP recovered only to the ini tial level. The downward spike like deflections on the CBV re cordings are artifacts due to the ET-1 injection. For abbrevia tions see the text. significantly inhibited (-1.8 ± 20.4 mm Hg; p < 0.05) by the pre administration of BQ-123 . The ini tial depressor effect of ET -1 ( -35.8 ± 11.9 mm Hg) was significantly blocked ( -4.8 ± 16.1 mm Hg; p < 0.01) by the preinjection of L-NMMA plus BQ-123 . Figure 5 summarizes the effects of intracarotid injection of ET -1 (3 nmol) on CBV, when compared between the groups without any pretreatment, with preadministration of BQ-123 (1 mg/kg), and with continuous injection of L-NMMA (0.3 5 mg/kg/min)
3. CBV changes following intracarotid injection of ei ther 0.01, 0.1, 1, or 3 nmol of ET-1 (n = 6). After the 0.01-or 0.1-nmol injection, CBV exhibited mild and continuous re ductions. After the 1-nmol injection, CBV was initially de creased, but subsequently recovered to the control level. Af ter the 3-nmol injection, CBV underwent a marked and tran sient reduction, but exhibited a significant increase thereafter. For abbreviations see the text.
plus preinjection of BQ-123 (1 mg/kg). Although the vasodilative effect of ET-l (+ 1.72 ± 1.42 vol% at 10 min) was not blocked by the preadministration of BQ-123 (+ 1.49 ± 1.92 vol%), it was significantly inhibited (+ 0.41 ± 0.54 vol%; p < 0. 05) by the preinjection of L-NMMA plus BQ-123 . There were no statistically significant changes in p a0 2' p a C 0 2' or pH before or after the injection of ET-l in any of the groups.
DISCUSSION
The photoelectric method permits continuous and quantitative measurements of the local CBV. CBV reflects the cumulative dimensions of the cerebrocortical microvessels. Intermittent CBF measurements are also possible by injecting small amounts of carbon-black solution into the carotid artery. The theory, validity, and application of this method have been discussed previously (Tomita et aI., 1978 (Tomita et aI., , 1982 (Tomita et aI., , 1983 . We have demonstrated that the insertion of the small lamp into the brain tissue does not affect the cerebrovascular responses, such as the autoregulation and CO2 reactivity of the CBF (Tomita et aI., 1978) . The CBF values measured by the photoelectric method were found to correlate well with the values determined by the hydrogen gas clearance method (Tomita et aI., 1988) .
The observation of mild but constant reductions in CBV, or constrictions of the cerebral microves sels, elicited by low doses (0.01-0.1 nmol) of intra carotidly injected ET -1 was not accompanied by changes in SABP. The response can therefore be MA8P when compared between the groups without any pre treatment (n = 6), with preadministration of 8Q-123 (1 mg/ kg) (n = 6), and with continuous injection of L-NMMA (0.35 mg/kg/min) plus preinjection of 8Q-123 (1 mg/kg) (n = 5). The pressor effect of ET-1 was significantly inhibited (p < 0.05) by the preadministration of 8Q-123. The initial transient depressor effect of ET-1 was significantly blocked (p < 0.01) by the preinjection of L-NMMA plus 8Q-123. For abbrevia tions see the text. attributed to the direct action of ET -I on the cere bral microvessels. This finding is consistent with those of Garda et ai. (1991) , who observed CBF reductions following intraarterial injection of vari ous amounts of ET-l (0.01-0.3 nmol), but contra dicts the results of Mima et ai. (1989) , who found no changes in the angiographically determined caliber of the basilar arteries. Since the degree of vasocon striction observed in the present study was small (-6-13 %), angiographical determination may not have been a suitable method. The discrepancies with the results of Gotoh et ai. (1991) , who detected no vasoconstrictive changes in the pial arteries after intracarotid injection of ET-l (0. 03 -3 nmol), may be due to the differences in vascular trees, viz., pial vessels versus the intraparenchymal microvascula ture, that were investigated by the two methods.
In the systemic circulation, the vasoconstrictive action of ET-l is considered to be mediated by the ETA receptors located in the vascular smooth mus cle (Sakurai et aI., 1992) . However, ET-l does not appear to cross the BBB (Koseki et aI., 1989) or to change its permeability (Faraci, 1989) . The problem thus remains of how the intravascular ET -1 gains access to the ET receptors in the cerebral vessels. i t is possible that ET-l may somehow cross the BBB and act directly on the ET receptors in the vascular smooth muscle (Garda et aI., 1991) , presumably of the ETA subtype. Some neurotoxins with a struc ture similar to that of ET are known to induce marked increases in the permeability of the BBB (Olesen and Crone, 1986) , and peptides have occa-sionally been shown to pass through the BBB (Hoffman et al., 1977) . The other possibility is that ET -1 may exert a vasoconstrictive action through the ET receptors located in the vascular endothe lium. The detailed distribution pattern and subtypes of ET receptors are not yet well understood in the cerebral vessels (Sakurai et al., 1992) .
Immediately after the intracarotid administration of high doses (3 nmol) of ET -1, significant decreases in CBV were observed. The CBV· reductions may have been due to the accompanying reductions in MABP, since the MABP was outside the accepted range of MABP for autoregulation of the CBF. Sub sequently, significant increases in CBV, or dilata tion of the cerebral microvessels, were observed. This is consistent with the observations of Gotoh et al. (1991) , who recorded a dilatation of the small pial arteries (�15%, but not statistically significant) following intracarotid injection of ET -1 (3 nmol) in cats. The cerebral vasodilatation was not secondary to the accompanying elevation of MABP, since the cerebral vasodilatation occurred even after the pre vention of MABP increases by the preadministra tion of BQ-123 . BQ-123 is a novel ET antagonist selective for the ETA receptor (Ihara et al., 1992) . Thus, the pressor effect of ET-l appears to be me diat;:d by the ETA receptors. BQ-153 , a compound similar to BQ-123 , has been shown to block the el evation of SABP elicited by ET -1 in rats (lhara et aI., 1992).
Dilatation of the cerebral microvessels, however, was inhibited by the continuous administration of L-NMMA in the presence of BQ-123 . L-NMMA competitively blocks the production of nitric oxide from L-arginine (Palmer et al., 1988) that may occur in the cerebrovascular endothelium, vascular smooth muscle, and perivascular nerve terminals (Bredt et al., 1990) . Nitric oxide has been proposed to be the EDRF in the cerebral vessels (Faraci, 1990; Prado et al., 1992) , although some authors support nitrosothiol as a candidate at least for ace tylcholine (Wei and Kontos, 1990; Rosenblum, 1992) . It seems likely, therefore, that nitric oxide, or EDRF, participated in the cerebral vasodilative effect of high doses of ET -1 observed in the present study. The systemic vasodilative action of ET -1, including the initial transient reductions of SABP, has been attributed to the secondary induction of EDRF (de Nucci et al., 1988; Wright and Fozard, 1988 ) mediated by the ET B receptors in the endo thelium (Sakamoto et al., 1991; Sakurai et al., 1992) . In fact, the initial depressor effect of ET-l was unaffected by the preadministration of ETA re ceptor antagonist (BQ-123 ), but was rather pre vented by the infusion of L-NMMA. It is possible, therefore, that induction of nitric oxide in the cere bral vessels following high doses of ET -1 is also mediated by the ET B receptors in the endothelium. We have demonstrated previously that intracarotid injection of neuropeptide Y also induced a transient cerebral vasodilatation mediated by nitric oxide (Kobari et al., 1993 ) .
In conclusion, intracarotidly administered ET-l gives rise to two different responses in feline cere bral microvessels, depending on the dose applied. Low doses of ET -1 elicit a mild vasoconstriction, probably mediated by ETA receptors, while high doses of ET -1 elicit a vasodilatation through ET B receptors and the induction of endothelial nitric ox ide.
